Pleased by the FDA’s acceptance of our IND for CLS-AX (axitinib injectable suspe…
[ad_1]
Pleased by the FDA’s acceptance of our IND for CLS-AX (axitinib injectable suspension), enabling initiation of a Phase 1/2a clinical trial in neovascular AMD by the end of 2020!
Our related recently-published ARVO abstract:
https://t.co/tR0Wd8yueY
#retina #biotech #medicine https://t.co/WiTT8ziDgs
[ad_2]
Source by Thomas Ciulla, MD, MBA